HMPL-523 is an oral small molecule therapy targeting Syk, a major component in the B-cell
IVL continues to present diagnostic challenges due to its elusive and diverse pathologic and clinical findings, and according to Ponzoni and colleagues (9), a comprehensive analysis is needed to find analogies and differences between the intravascular and extravascular components of large B-cell
lymphomas to further characterize them and potentially formulate more focused treatment depending on each patient's unique presentation.
Researchers correlated B-cell
levels to the total number of new brain lesions that appeared on magnetic resonance imaging.
Dr Axel Kallies, Associate Professor David Tarlinton, Dr Stephen Nutt and colleagues made the discovery while investigating the development of B-cell
When H/DS is associated with an indolent B-cell
leukemia/lymphoma, either metachronous or concurrent, the issue of its clonal relationship with the primary B-cell
neoplasm is raised.
The repeat biopsy led to a final pathologic diagnosis of a low-grade B-cell
lymphoma consistent with marginal-zone lymphoma (figure 2).
The single-agent phase II study is designed to assess the antitumor activity, tolerability and pharmacokinetic profile of SGN-40 in patients with relapsed or refractory diffuse large B-cell
Extensive clinical studies of ZEVALIN have confirmed high response rates and durable responses in patients with relapsed, refractory follicular or transformed B-cell
In Zurich, we regularly screen all B-cell
lymphoma patients by serology and by PCR [polymerase chain reaction] of a biopsy specimen for Borrelia burgdorferi, and occasionally, we do see regression of Borrelia-positive B-cell
lymphomas upon doxycycline-based therapy over 3-6 weeks," explained Dr.
While eliminating a major class of immune cells sounds drastic, scientists have unexpectedly found that B-cell
depletion doesn't leave the human body vulnerable to infectious disease.
Normal numbers of pro-B, pre-B, and surface immunoglobulin-positive B cells exist in the bone marrow, while peripheral B-cell
numbers are significantly reduced (30% of normal).
Senesco" or the "Company") (NYSE MKT: SNT) reported today that the clinical trial of SNS01-T has been expanded to include diffuse large B-cell
lymphoma (DLBCL) and mantle cell lymphoma (MCL).